High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience.
Eur J Haematol Suppl
; 64: 3-7, 2001 Jul.
Article
en En
| MEDLINE
| ID: mdl-11486398
ABSTRACT
Autologous stem-cell transplantation (ASCT) has permitted to deliver high-dose therapy (HDT). In aggressive lymphomas, the GELA group conducted prospective and retrospective studies comparing HDT + ASCT to conventional sequential chemotherapy. In relapsing patients and in partial remission, retrospective studies showed a survival advantage for HDT + ASCT over sequential chemotherapy. In complete response, advantage for HDT + ASCT was demonstrated in a prospective trial only for patients with high intermediate or high risk in the IPI score. The attainment of a maximal reduction of the tumoral mass before going HDT is very important either in first line or in relapsing patients.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Antineoplásicos
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Eur J Haematol Suppl
Asunto de la revista:
HEMATOLOGIA
Año:
2001
Tipo del documento:
Article
País de afiliación:
Bélgica